Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Update

Kronos Bio, Inc. (NASDAQ:KRON) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 758,500 shares, an increase of 7.7% from the August 15th total of 704,500 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average trading volume of 298,900 shares, the short-interest ratio is presently 2.5 days.

Insider Buying and Selling at Kronos Bio

In other Kronos Bio news, CEO Norbert W. Bischofberger acquired 410,848 shares of the firm’s stock in a transaction dated Thursday, June 27th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $480,692.16. Following the acquisition, the chief executive officer now owns 10,597,468 shares in the company, valued at approximately $12,399,037.56. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 23.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in KRON. Virtu Financial LLC purchased a new stake in shares of Kronos Bio in the first quarter valued at about $71,000. Marquette Asset Management LLC boosted its position in shares of Kronos Bio by 19.8% during the 1st quarter. Marquette Asset Management LLC now owns 80,369 shares of the company’s stock worth $104,000 after acquiring an additional 13,269 shares in the last quarter. Forefront Analytics LLC increased its holdings in shares of Kronos Bio by 75.0% in the 2nd quarter. Forefront Analytics LLC now owns 134,998 shares of the company’s stock valued at $167,000 after acquiring an additional 57,867 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Kronos Bio by 17.2% during the 1st quarter. Acadian Asset Management LLC now owns 774,559 shares of the company’s stock worth $1,005,000 after acquiring an additional 113,618 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Kronos Bio by 14.6% during the first quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company’s stock worth $2,533,000 after purchasing an additional 247,918 shares in the last quarter. 64.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $2.25 price target on shares of Kronos Bio in a research note on Monday, August 19th.

Kronos Bio Stock Down 2.4 %

Shares of Kronos Bio stock traded down $0.02 on Wednesday, reaching $0.92. 35,149 shares of the stock were exchanged, compared to its average volume of 309,244. The business has a 50 day moving average price of $1.12 and a two-hundred day moving average price of $1.09. The firm has a market capitalization of $55.28 million, a price-to-earnings ratio of -0.46 and a beta of 1.87. Kronos Bio has a twelve month low of $0.69 and a twelve month high of $1.60.

Kronos Bio (NASDAQ:KRON) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. Kronos Bio had a negative net margin of 1,222.83% and a negative return on equity of 68.82%. The business had revenue of $2.69 million for the quarter, compared to the consensus estimate of $1.75 million. Research analysts forecast that Kronos Bio will post -1.33 EPS for the current year.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.